Guidelines based on pharmacogenomic testing
are not in tomorrow’s healthcare plans.
They’re in today’s labels.

 
 

  
Personalize Your Patient

          Personalize Your Care

  
1. Abilify Maintena [package insert]. Otsuka America Pharmaceutical, Inc., Rockville, MD; February 2013. http://www.otsuka-us.com/Products/Documents/Abilify.M.PI.pdf.
Accessed August 13, 2013.
2. Celebrex [package insert]. Pfizer, Inc., New York, NY; January 2013. http://labeling.pfizer.com/ShowLabeling.aspx?id=793. Accessed August 13, 2013.
3. Coumadin [package insert]. Bristol-Myers Squibb, Princeton, NJ; October 2011. http://packageinserts.bms.com/pi/pi_coumadin.pdf. Accessed August 13, 2013.
4. Zelboraf [package insert]. Genentech USA, Inc., South San Francisco, CA; 2013. http://www.gene.com/download/pdf/zelboraf_prescribing.pdf. Accessed August 26, 2013.
5. Celexa [package insert]. Forest Laboratories, Inc., St. Louis, MO; December 2012. http://www.frx.com/pi/celexa_pi.pdf. Accessed August 13, 2013.
6. Gleevec [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, NJ; July 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021588s038lbl.pdf.
Accessed August 13, 2013.